IASLC TTLC 2022 | Immunotherapy as combination and neoadjuvant therapies in NSCLC

Jay Lee, MD, University of California, Los Angeles, CA, discusses the role of immunotherapies in various settings to treat non-small cell lung cancer (NSCLC). Multiple trials including the Phase III CheckMate 816 trial (NCT02998528) of ipilimumab or nivolumab with chemotherapy have demonstrated the superiority of combining checkpoint inhibitors with chemotherapy, especially in stage II/II lung cancer. Whilst the use of adjuvant immunotherapy still remains under investigation, neoadjuvant immunotherapy has proven to be effective, with data from the IMpower010 (NCT02486718) and KEYNOTE-091 (NCT02504372) trials assessing atezolizumab and pembrolizumab respectively. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).